CA2618488A1 - Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual - Google Patents

Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual Download PDF

Info

Publication number
CA2618488A1
CA2618488A1 CA002618488A CA2618488A CA2618488A1 CA 2618488 A1 CA2618488 A1 CA 2618488A1 CA 002618488 A CA002618488 A CA 002618488A CA 2618488 A CA2618488 A CA 2618488A CA 2618488 A1 CA2618488 A1 CA 2618488A1
Authority
CA
Canada
Prior art keywords
bone mass
seq
compound
vertebrate
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002618488A
Other languages
French (fr)
Other versions
CA2618488C (en
Inventor
Zhi-Liang Chu
James N. Leonard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arena Pharmaceuticals Inc
Original Assignee
Arena Pharmaceuticals, Inc.
Zhi-Liang Chu
James N. Leonard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharmaceuticals, Inc., Zhi-Liang Chu, James N. Leonard filed Critical Arena Pharmaceuticals, Inc.
Publication of CA2618488A1 publication Critical patent/CA2618488A1/en
Application granted granted Critical
Publication of CA2618488C publication Critical patent/CA2618488C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/108—Osteoporosis

Abstract

The present invention relates to methods of using GPR119 receptor to identify compounds useful for increasing bone mass in an individual. Agonists of GPR119 receptor are useful as therapeutic agents for treating or preventing a condition characterized by low bone mass, such as osteoporosis, and for increasing bone mass in an individual. Agonists of GPR119 receptor promote bone formation in an individual.

Claims (73)

1. A method for identifying GIP secretagogues, compounds useful for preventing or treating a condition characterized by low bone mass, or compounds useful for increasing bone mass in an individual, comprising the steps of:
(a) contacting a test compound with a host cell or with membrane of a host cell comprising a G protein-coupled receptor, wherein the G protein-coupled receptor comprises an amino acid sequence selected from the group consisting of:
(i) amino acids 1-335 of SEQ ID NO:2;
(ii) amino acids 2-335 of SEQ ID NO:2;
(iii) amino acids 2-335 of SEQ ID NO:2, with the proviso that the receptor does not comprise the amino acid sequence of SEQ ID
NO:2;
(iv) the amino acid sequence of a G protein-coupled receptor encoded by a polynucleotide that is amplifiable by polymerase chain reaction (PCR) on a human DNA sample using specific primers SEQ ID
NO:3 and SEQ ID NO:4;
(v) the amino acid sequence of a G protein-coupled receptor encoded by a polynucleotide hybridizing under conditions of high stringency to the complement of SEQ ID NO:1;
(vi) a variant of SEQ ID NO: 2;
(vii) the amino acid sequence of (vi) when selected from the group consisting of:
(a') the amino acid sequence of a G protein-coupled receptor having at least about 80% identity to SEQ ID NO: 2; and (b') the amino acid sequence of a G protein-coupled receptor comprising at least 20 contiguous amino acids of SEQ ID
NO: 2;
(viii) the amino acid sequence of a constitutively active version of a G
protein-coupled receptor having SEQ ID NO: 2; and (ix) a biologically active fragment of any one of (i) to (viii); and (b) determining the ability of the test compound to stimulate functionality of the receptor;

wherein the ability of the test compound to stimulate functionality of the receptor is indicative of the test compound being a GIP secretagogue, a compound useful for treating or preventing a condition characterized by low bone mass, or a compound useful for increasing bone mass in an individual.
2. A method for identifying GIP secretagogues, compounds useful for preventing or treating a condition characterized by low bone mass, or compounds useful for increasing bone mass in an individual, comprising the steps of the method of claim 1, and further comprising:
(c) contacting a compound which stimulates functionality of the receptor in step (b) in vitro with a vertebrate enteroendocrine cell; and (d) determining whether the compound stimulates GIP secretion from the vertebrate enteroendocrine cell;
wherein the ability of the test compound to stimulate GIP secretion from the vertebrate enteroendocrine cell is indicative of the test compound being a GIP
secretagogue, a compound useful for treating or preventing a condition characterized by low bone mass, or a compound useful for increasing bone mass in an individual.
3. A method for identifying GIP secretagogues, compounds useful for preventing or treating a condition characterized by low bone mass, or compounds useful for increasing bone mass in an individual, comprising the steps of the method of claim 1, and further comprising:
(c) administering a compound which stimulates functionality of the receptor in step (b) to a vertebrate; and (d) determining whether the compound increases a GIP level in the vertebrate;
wherein the ability of the test compound to increase a GIP level in the vertebrate is indicative of the test compound being a GIP secretagogue, a compound useful for treating or preventing a condition characterized by low bone mass, or a compound useful for increasing bone mass in an individual.
4. A method in accordance with claim 3, wherein the vertebrate is a non-human vertebrate.
5. A method for identifying compounds useful for preventing or treating a condition characterized by low bone mass or compounds useful for increasing bone mass in an individual, comprising the steps of the method of claim 1, and further comprising:
(c) administering a compound which stimulates functionality of the receptor in step (b) to a vertebrate; and (d) determining whether the compound increases a level of bone mass in the vertebrate;

wherein the ability of the test compound to increase a level of bone mass1 in the vertebrate is indicative of the test compound being a compound useful for treating or preventing a condition characterized by low bone mass or a compound useful for increasing bone mass in an individual.
6. The method of claim 5, wherein the vertebrate is a non-human vertebrate.
7. The method of any one of claims 1 to 6, wherein the receptor is recombinant.
8. The method of any one of claims 1 to 7, wherein the host cell comprises an expression vector, said expression vector comprising a polynucleotide encoding the G
protein-coupled receptor.
9. The method of any one of claims 1 to 8, wherein said determining is through the measurement of the level of a second messenger.
10. The method of claim 9, wherein the second messenger is selected from the group consisting of cyclic AMP (cAMP), cyclic GMP (cGMP), inositol 1,4,5-triphosphate (IP3), diacylglycerol (DAG), MAP kinase activity, MAPK/ERK kinase kinase-1 (MEKK1) activity, and Ca2+.
11. The method of claim 10, wherein a level of cAMP is increased.
12. The method of any one of claims 1 to 8, wherein said determining is through the use of a Melanophore assay, through the measurement of GTP.gamma.S binding to a membrane comprising said GPCR, or through a reporter assay.
13. A method in accordance with any one of claims 1 to 12, wherein the host cell is a mammalian host cell.
14. A method in accordance with any one of claims 1 to 12, wherein the host cell is a yeast host cell.
15. A method in accordance with any one of claims 1 to 12, wherein the host cell is a melanophore host cell.
16. The method of any one of claims 1 to 15, wherein the test compound is a small molecule.
17. The method of any one of claims 1 to 16, wherein the receptor comprises the amino acid sequence of a G protein-coupled receptor having at least about 80% identity to SEQ ID NO: 2.
18. The method of any one of claims 1 to 17, wherein the receptor comprises the amino acid sequence of SEQ ID NO: 2.
19. A method for identifying GIP secretagogues, compounds useful for preventing or treating a condition characterized by low bone mass, or compounds useful for increasing bone mass in an individual, comprising the steps of:
(a) contacting a compound in vitro with a vertebrate enteroendocrine cell, said compound having been identified by a method according to claim 1; and (b) determining whether the compound stimulates GIP secretion from the vertebrate enteroendocrine cell;
wherein the ability of the test compound to stimulate GIP secretion from the vertebrate enteroendocrine cell is further indicative of the test compound being a GIP
secretagogue, a compound useful for treating or preventing a condition characterized by low bone mass, or a compound useful for increasing bone mass in an individual.
20. A method for identifying GIP secretagogues, compounds useful for preventing or treating a condition characterized by low bone mass, or compounds useful for increasing bone mass in an individual, comprising the steps of:
(a) administering a compound to a vertebrate, said compound having been identified by a method according to claim 1; and (b) determining whether the compound increases a GIP level in the vertebrate;
wherein the ability of the test compound to increase a GIP level in the vertebrate is further indicative of the test compound being a GIP secretagogue, a compound useful for treating or preventing a condition characterized by low bone mass, or a compound useful for increasing bone mass in an individual.
21. A method in accordance with claim 20, wherein the vertebrate is a non-human vertebrate.
22. A method for identifying compounds useful for preventing or treating a condition characterized by low bone mass or compounds useful for increasing bone mass in an individual, comprising the steps of:
(a) administering a compound to a vertebrate, said compound having been identified by a method according to claim 1; and (b) determining whether the compound increases a level of bone mass in the vertebrate;
wherein the ability of the test compound to increase a level of bone mass in the vertebrate is further indicative of the test compound being a compound useful for treating or preventing a condition characterized by low bone mass or a compound useful for increasing bone mass in an individual.
23. The method of claim 22, wherein the vertebrate is a non-human vertebrate.
24. A method according to any one of claims 19 to 23, wherein the test compound is a small molecule.
25. A method for identifying GIP secretagogues, compounds useful for preventing or treating a condition characterized by low bone mass, or compounds useful for increasing bone mass in an individual, comprising the steps of:
(a) contacting a GPR119 agonist in vitro with a vertebrate enteroendocrine cell; and (b) determining whether the GPR119 agonist stimulates GIP secretion from the vertebrate enteroendocrine cell;
wherein the ability of the GPR119 agonist to stimulate GIP secretion from the vertebrate enteroendocrine cell is indicative of the GPR119 agonist being a GIP
secretagogue, a compound useful for treating or preventing a condition characterized by low bone mass, or a compound useful for increasing bone mass in an individual.
26. A method for identifying GIP secretagogues, compounds useful for preventing or treating a condition characterized by low bone mass, or compounds useful for increasing bone mass in an individual, comprising the steps of:
(a) administering a GPR119 agonist to a vertebrate; and (b) determining whether the GPR119 agonist increases a GIP level in the vertebrate;
wherein the ability of the GPR119 agonist to increase a GIP level in the vertebrate is indicative of the GPR119 agonist being a GIP secretagogue, a compound useful for treating or preventing a condition characterized by low bone mass, or a compound useful for increasing bone mass in an individual.
27. A method in accordance with claim 26, wherein the vertebrate is a non-human vertebrate.
28. A method for identifying compounds useful for preventing or treating a condition characterized by low bone mass or compounds useful for increasing bone mass in an individual, comprising the steps of:
(a) administering a GPR119 agonist to a vertebrate; and (b) determining whether the GPR119 agonist increases a level of bone mass in the vertebrate;
wherein the ability of the GPR119 agonist to increase a level of bone mass in the vertebrate is indicative of the GPR119 agonist being a compound useful for treating or preventing a condition characterized by low bone mass or a compound useful for increasing bone mass in an individual.
29. The method of claim 28, wherein the vertebrate is a non-human vertebrate.
30. A method according to any one of claims 25 to 29, wherein the GPR119 agonist is an agonist of human GPR119.
31. A method according to any one of claims 25 to 30, wherein the GPR119 agonist is a selective GPR119 agonist.
32. A method according to any one of claims 25 to 31, wherein the GPR119 agonist has an EC50 of less than a value selected from the group consisting of 10 µM, 1 µM and 100 nM.
33. A method according to any one of claims 25 to 32, wherein the GPR119 agonist is a small molecule.
34. A method for identifying GIP secretagogues, compounds useful for preventing or treating a condition characterized by low bone mass, or compounds useful for increasing bone mass in an individual, comprising the steps of:
(a) contacting a G protein-coupled receptor with an optionally labeled known ligand to the receptor in the presence or absence of a test compound, wherein the G protein-coupled receptor comprises an amino acid sequence selected from the group consisting of:
(i) amino acids 1-335 of SEQ ID NO:2;
(ii) amino acids 2-335 of SEQ ID NO:2;

(iii) amino acids 2-335 of SEQ ID NO:2, with the proviso that the receptor does not comprise the amino acid sequence of SEQ ID
NO:2;
(iv) the amino acid sequence of a G protein-coupled receptor encoded by a polynucleotide that is amplifiable by polymerase chain reaction (PCR) on a human DNA sample using specific primers SEQ ID
NO:3 and SEQ ID NO:4;
(v) the amino acid sequence of a G protein-coupled receptor encoded by a polynucleotide hybridizing under conditions of high stringency to the complement of SEQ ID NO:1;
(vi) a variant of SEQ ID NO: 2;
(vii) the amino acid sequence of (vi) when selected from the group consisting of:
(a') the amino acid sequence of a G protein-coupled receptor having at least about 80% identitiy to SEQ ID NO: 2; and (b') the amino acid sequence of a G protein-coupled receptor comprising at least 20 contiguous amino acids of SEQ ID
NO: 2;
(viii) the amino acid sequence of a constitutively active version of a G
protein-coupled receptor having SEQ ID NO: 2; and (ix) a biologically active fragment of any one of (i) to (viii); and (b) detecting the complex between said known ligand and said receptor; and (c) determining whether less of said complex is formed in the presence of the test compound than in the absence of the test compound;
wherein said determination is indicative of the test compound being a GIP
secretagogue, a compound useful for treating or preventing a condition characterized by low bone mass, or a compound useful for increasing bone mass in an individual.
35. A method for identifying GIP secretagogues, compounds useful for preventing or treating a condition characterized by low bone mass, or compounds useful for increasing bone mass in an individual, comprising the steps of the method of claim 34, and further comprising:
(d) contacting a compound in the presence of which less of said complex is formed in step (c) in vitro with a vertebrate enteroendocrine cell; and (e) determining whether the compound stimulates GIP secretion from the vertebrate enteroendocrine cell;

wherein the ability of the test compound to stimulate GIP secretion from the vertebrate enteroendocrine cell is indicative of the test compound being a GI P
secretagogue, a compound useful for treating or preventing a condition characterized by low bone mass, or a compound useful for increasing bone mass in an individual.
36. A method for identifying GIP secretagogues, compounds useful for preventing or treating a condition characterized by low bone mass, or compounds useful for increasing bone mass in an individual, comprising the steps of the method of claim 34, and further comprising:
(d) administering a compound in the presence of which less of said complex is formed in step (c) to a vertebrate; and (e) determining whether the compound increases a GIP level in the vertebrate;
wherein the ability of the test compound to increase a GIP level in the vertebrate is indicative of the test compound being a GIP secretagogue, a compound useful for treating or preventing a condition characterized by low bone mass, or a compound useful for increasing bone mass in an individual.
37. A method in accordance with claim 36, wherein the vertebrate is a non-human vertebrate.
38. A method for identifying compounds useful for preventing or treating a condition characterized by low bone mass or compounds useful for increasing bone mass in an individual, comprising the steps of the method of claim 34, and further comprising:
(d) administering a compound in the presence of which less of said complex is formed in step (c) to a vertebrate; and (e) determining whether the compound increases a level of bone mass in the vertebrate;
wherein the ability of the test compound to increase a level of bone mass in the vertebrate is indicative of the test compound being a compound useful for treating or preventing a condition characterized by low bone mass or a compound useful for increasing bone mass in an individual.
39. A method in accordance with claim 38, wherein the vertebrate is a non-human vertebrate.
40. The method of any one of claims 34 to 39, wherein the receptor is recombinant.
41. The method of any one of claims 34 to 40, wherein the host cell comprises an expression vector, said expression vector comprising a polynucleotide encoding the G
protein-coupled receptor.
42. The method of any one of claims 34 to 41, wherein the known ligand is a agonist.
43. The method of claim 42, wherein the GPR119 agonist is an agonist of human GPR119.
44. The method of claim 42 or claim 43, wherein the GPR119 agonist has an EC50 of less than a value selected from the group consisting of 10 µM, 1 µM and 100 nM.
45. The method of any one of claims 42 to 44, wherein the GPR119 agonist is a small molecule.
46. The method of any one of claims 34 to 45, wherein the test compound is a small molecule.
47. The method of any one of claims 34 to 46, wherein the receptor comprises the amino acid sequence of a G protein-coupled receptor having at least about 80%
identity to SEQ ID NO:
2.
48. The method of any one of claims 34 to 47, wherein the receptor comprises the amino acid sequence of SEQ ID NO: 2.
49. A method of screening test compounds to identify a GIP secretagogue, a compound for treating or preventing a condition characterized by low bone mass, or a compound for increasing bone mass in an individual, which is characterized by using a G protein-coupled receptor comprising an amino acid sequence selected from the group consisting of:
(a) amino acids 1-335 of SEQ ID NO: 2;
(b) amino acids 2-335 of SEQ ID NO: 2;
(c) amino acids 2-335 of SEQ ID NO: 2, wherein the GPCR does not comprise the amino acid sequence of SEQ ID NO: 2;
(d) the amino acid sequence of a G protein-coupled receptor encoded by a polynucleotide that is amplifiable by polymerase chain reaction (PCR) on a human DNA sample using specific primers SEQ ID NO: 3 and SEQ ID NO: 4;

(e) the amino acid sequence of a G protein-coupled receptor encoded by a polynucleotide hybridizing under conditions of high stringency to the complement of SEQ ID NO: 1;
(f) a variant of SEQ ID NO: 2;
(g) the amino acid sequence of (f) when selected from the group consisting of:
(i) the amino acid sequence of a G protein-coupled receptor having at least about 80% identity to SEQ ID NO: 2; and (ii) the amino acid sequence of a G protein coupled receptor comprising at least 20 contiguous amino acids of SEQ ID NO: 2;
(h) the amino acid sequence of a constitutively active version of a G protein-coupled receptor having SEQ ID NO: 2; and (i) a biologically active fragment of any one of any one of (a) to (h).
50. The method of claim 49, wherein the receptor comprises the amino acid sequence of a G
protein-coupled receptor having at least about 80% identity to SEQ ID NO: 2.
51. The method of claim 49 or claim 50, wherein the receptor comprises the amino acid sequence of SEQ ID NO: 2.
52. Use of a G protein-coupled receptor to screen test compounds as GIP
secretagogues, compounds for treating or preventing a condition characterized by low bone mass, or compounds for increasing bone mass in an individual, wherein the G protein-coupled receptor comprises an amino acid sequence selected from the group consisting of:
(a) amino acids 1-335 of SEQ ID NO: 2;
(b) amino acids 2-335 of SEQ ID NO: 2;
(c) amino acids 2-335 of SEQ ID NO: 2, wherein the GPCR does not comprise the amino acid sequence of SEQ ID NO: 2;
(d) the amino acid sequence of a G protein-coupled receptor encoded by a polynucleotide that is amplifiable by polymerase chain reaction (PCR) on a human DNA sample using specific primers SEQ ID NO: 3 and SEQ ID NO: 4;
(e) the amino acid sequence of a G protein-coupled receptor encoded by a polynucleotide hybridizing under conditions of high stringency to the complement of SEQ ID NO: 1;
(f) a variant of SEQ ID NO: 2;
(g) the amino acid sequence of (f) when selected from the group consisting of:
(i) the amino acid sequence of a G protein-coupled receptor having at least about 80% identity to SEQ ID NO: 2; and (ii) the amino acid sequence of a G protein-coupled receptor comprising at least 20 contiguous amino acids of SEQ ID NO: 2;
(h) the amino acid sequence of a constitutively active version of a G protein-coupled receptor having SEQ ID NO: 2; and (i) a biologically active fragment of any one of any one of (a) to (h).
53. Use according to claim 52, wherein the test compound is a GPR119 agonist.
54. Use according to claim 53, wherein the GPR119 agonist is an agonist of human GPR119.
55. Use according to claim 53 or claim 54, wherein the GPR119 agonist has an EC50 of less than a value selected from the group consisting of 10 µM, 1 µM and 100 nM.
56. Use according to any one of claims 52 to 55, wherein the test compound is a small molecule.
57. Use according to any one of claims 52 to 56, wherein the receptor comprises the amino acid sequence of a G protein-coupled receptor having at least about 80%
identity to SEQ ID NO:
2.
58. Use according to any one of claims 52 to 57, wherein the receptor comprises the amino acid sequence of SEQ ID NO: 2.
59. Use according to any one of claims 52 to 58, wherein the receptor is recombinant.
60. A method for identifying GIP secretagogues, compounds useful for treating or preventing a condition characterized by low bone mass, or compounds useful for increasing bone mass in an individual, coinprising the steps of:
(a) contacting a compound which stimulates functionality of a G protein-coupled receptor, wherein said G protein-coupled receptor comprises an amino acid sequence selected from the group consisting of:
(i) amino acids 1-335 of SEQ ID NO:2;
(ii) amino acids 2-335 of SEQ ID NO:2;
(iii) amino acids 2-335 of SEQ ID NO:2, with the proviso that the G
protein-coupled receptor does not comprise the amino acid sequence of SEQ ID NO:2;

(iv) the amino acid sequence of a G protein-coupled receptor encoded by a polynucleotide that is amplifiable by polymerase chain reaction (PCR) on a human DNA sample using specific primers SEQ ID
NO:3 and SEQ ID NO:4;
(xiv) the amino acid sequence of a G protein-coupled receptor encoded by a polynucleotide hybridizing under conditions of high stringency to the complement of SEQ ID NO:1;
(xv) a variant of SEQ ID NO: 2;
(xvi) the amino acid sequence of (vi) when selected from the group consisting of:
(a') the amino acid sequence of a G protein-coupled receptor having at least about 80% identity to SEQ ID NO: 2; and (b') an amino acid sequence of a G protein-coupled receptor comprising at least 20 contiguous amino acids of SEQ ID
NO: 2;
(viii) the amino acid sequence of a constitutively active version of a G
protein-coupled receptor having SEQ ID NO: 2; and (ix) a biologically active fragment of any one of (i) to (viii);
in vitro with a vertebrate enteroendocrine cell or with a cell capable of secreting GIP, said compound having been determined by a method according to claim 1;
and (b) determining whether the compound stimulates GIP secretion from the vertebrate enteroendocrine cell or from the cell capable of secreting GIP;
wherein the ability of the test compound to stimulate GIP secretion from the vertebrate enteroendocrine cell or from the cell capable of secreting GIP is further indicative of the test compound being a GIP secretagogue, a compound useful for treating or preventing a condition characterized by low bone mass, or a compound useful for increasing bone mass in an individual.
61. A method for identifying GIP secretagogues, compounds useful for treating or preventing a condition characterized by low bone mass, or compounds useful for increasing bone mass in an individual, comprising the steps of:
(a) administering to a vertebrate a compound which stimulates functionality of a G
protein-coupled receptor, wherein said G protein-coupled receptor comprises an amino acid sequence selected from the group consisting of:
(i) amino acids 1-335 of SEQ ID NO:2;
(ii) amino acids 2-335 of SEQ ID NO:2;

(iii) amino acids 2-335 of SEQ ID NO:2, with the proviso that the G
protein-coupled receptor does not comprise the amino acid sequence of SEQ ID NO:2;
(iv) the amino acid sequence of a G protein-coupled receptor encoded by a polynucleotide that is amplifiable by polymerase chain reaction (PCR) on a human DNA sample using specific primers SEQ ID
NO:3 and SEQ ID NO:4;
(xvii) the amino acid sequence of a G protein-coupled receptor encoded by a polynucleotide hybridizing under conditions of high stringency to the complement of SEQ ID NO:1;
(xviii) a variant of SEQ ID NO: 2;
(xix) the amino acid sequence of (vi) when selected from the group consisting of:
(a') the amino acid sequence of a G protein-coupled receptor having at least about 80% identity to SEQ ID NO: 2; and (b') an amino acid sequence of a G protein-coupled receptor comprising at least 20 contiguous amino acids of SEQ ID
NO: 2;
(viii) the amino acid sequence of a constitutively active version of a G
protein-coupled receptor having SEQ ID NO: 2; and (ix) a biologically active fragment of any one of (i) to (viii);
said compound having been determined by a method according to claim 1; and (b) determining whether the compound increases a GIP level in the vertebrate;
wherein the ability of the test compound to increase a GIP level in the vertebrate is further indicative of the test compound being a GIP secretagogue, a compound useful for treating or preventing a condition characterized by low bone mass, or a compound useful for increasing bone mass in an individual.
62. A method according to claim 61, wherein the vertebrate is a non-human vertebrate.
63. A method for identifying GIP secretagogues, compounds useful for treating or preventing a condition characterized by low bone mass, or compounds useful for increasing bone mass in an individual, comprising the steps of:
(a) administering to a vertebrate a compound which stimulates functionality of a G
protein-coupled receptor, wherein said G protein-coupled receptor comprises an amino acid sequence selected from the group consisting of:
(i) amino acids 1-335 of SEQ ID NO:2;

(ii) amino acids 2-335 of SEQ ID NO:2;
(iii) amino acids 2-335 of SEQ ID NO:2, with the proviso that the G
protein-coupled receptor does not comprise the amino acid sequence of SEQ ID NO:2;
(iv) the amino acid sequence of a G protein-coupled receptor encoded by a polynucleotide that is amplifiable by polymerase chain reaction (PCR) on a human DNA sample using specific primers SEQ ID
NO:3 and SEQ ID NO:4;
(xx) the amino acid sequence of a G protein-coupled receptor encoded by a polynucleotide hybridizing under conditions of high stringency to the complement of SEQ ID NO:1;
(xxi) a variant of SEQ ID NO: 2;
(xxii) the amino acid sequence of (vi) when selected from the group consisting of:
(a') the amino acid sequence of a G protein-coupled receptor having at least about 80% identity to SEQ ID NO: 2; and (b') an amino acid sequence of a G protein-coupled receptor comprising at least 20 contiguous amino acids of SEQ ID
NO: 2;
(viii) the amino acid sequence of a constitutively active version of a G
protein-coupled receptor having SEQ ID NO: 2; and (ix) a biologically active fragment of any one of (i) to (viii);
said compound having been determined by a method according to claim 1; and (b) determining whether the compound increases a level of bone mass in the vertebrate;
wherein the ability of the test compound to increase a level of bone mass in the vertebrate is further indicative of the test compound being a compound useful for treating or preventing a condition characterized by low bone mass or a compound useful for increasing bone mass in an individual.
64. A method according to claim 63, wherein the vertebrate is a non-human vertebrate.
65. A method according to any one of claims 60 to 64, wherein the test compound is a small molecule.
66. A method according to any one of claims 60 to 65, wherein the receptor comprises the amino acid sequence of a G protein-coupled receptor having at least about 80% identity to SEQ ID NO: 2.
67. A method according to any one of claims 60 to 66, wherein the receptor comprises the amino acid sequence of SEQ ID NO: 2.
68. A method for identifying GIP secretagogues, compounds useful for preventing or treating a condition characterized by low bone mass, or compounds useful for increasing bone mass in an individual, comprising the steps of:
(a) contacting a compound in vitro with a vertebrate enteroendocrine cell, said compound having been identified by a method according to claim 34; and (b) determining whether the compound stimulates GIP secretion from the vertebrate enteroendocrine cell or from the cell capable of secreting GIP;
wherein the ability of the test compound to stimulate GIP secretion from the vertebrate enteroendocrine cell is further indicative of the test compound being a GIP
secretagogue, a compound useful for treating or preventing a condition characterized by low bone mass, or a compound useful for increasing bone mass in an individual.
69. A method for identifying GIP secretagogues, compounds useful for preventing or treating a condition characterized by low bone mass, or compounds useful for increasing bone mass in an individual, comprising the steps of:
(a) administering a compound to a vertebrate, said compound having been identified by a method according to claim 34; and (b) determining whether the compound increases a GIP level in the vertebrate;
wherein the ability of the test compound to increase a GIP level in the vertebrate is further indicative of the test compound being a GIP secretagogue, a compound useful for treating or preventing a condition characterized by low bone mass, or a compound useful for increasing bone mass in an individual.
70. A method according to claim 69, wherein the vertebrate is a non-human vertebrate.
71. A method for identifying GIP secretagogues, compounds useful for preventing or treating a condition characterized by low bone mass, or compounds useful for increasing bone mass in an individual, comprising the steps of:

(a) administering a compound to a vertebrate, said compound having been identified by a method according to claim 34; and (b) determining whether the compound increases a level of bone mass in the vertebrate;
wherein the ability of the test compound to increase a level of bone mass in the vertebrate is further indicative of the test compound being a GIP secretagogue, a compound useful for treating or preventing a condition characterized by low bone mass, or a compound useful for increasing bone mass in an individual.
72. A method according to claim 71, wherein the vertebrate is a non-human vertebrate.
73. A method according to any one of claims 68 to 72, wherein the test compound is a small molecule.
CA2618488A 2006-04-11 2007-04-10 Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual Expired - Fee Related CA2618488C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79155006P 2006-04-11 2006-04-11
US60/791,550 2006-04-11
PCT/US2007/008902 WO2007120689A2 (en) 2006-04-11 2007-04-10 Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual

Publications (2)

Publication Number Publication Date
CA2618488A1 true CA2618488A1 (en) 2007-10-25
CA2618488C CA2618488C (en) 2010-07-13

Family

ID=38442009

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2618488A Expired - Fee Related CA2618488C (en) 2006-04-11 2007-04-10 Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual

Country Status (36)

Country Link
US (5) US7833730B2 (en)
EP (4) EP1971862B1 (en)
JP (6) JP4521838B2 (en)
KR (1) KR101281962B1 (en)
CN (3) CN101421618B (en)
AR (1) AR060406A1 (en)
AT (1) ATE487940T1 (en)
AU (1) AU2007238805B2 (en)
BR (1) BRPI0710597A2 (en)
CA (1) CA2618488C (en)
CL (1) CL2007001011A1 (en)
CR (1) CR10337A (en)
CY (1) CY1111123T1 (en)
DE (1) DE602007010420D1 (en)
DK (1) DK1971862T3 (en)
EA (2) EA016041B1 (en)
EC (1) ECSP088817A (en)
ES (1) ES2354390T3 (en)
GT (1) GT200800207A (en)
HK (1) HK1117911A1 (en)
HR (1) HRP20110068T1 (en)
MA (1) MA30555B1 (en)
ME (1) MEP27308A (en)
MX (1) MX2008013120A (en)
NO (1) NO20084746L (en)
NZ (1) NZ571110A (en)
PL (1) PL1971862T3 (en)
PT (1) PT1971862E (en)
RS (1) RS51745B (en)
SG (1) SG10201404220TA (en)
SI (1) SI1971862T1 (en)
TN (1) TNSN08396A1 (en)
TW (1) TWI409458B (en)
UA (1) UA97479C2 (en)
WO (1) WO2007120689A2 (en)
ZA (1) ZA200807997B (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS20050532A (en) 2003-01-14 2007-12-31 Arena Pharmaceuticals Inc., 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
DOP2006000008A (en) * 2005-01-10 2006-08-31 Arena Pharm Inc COMBINED THERAPY FOR THE TREATMENT OF DIABETES AND RELATED AFFECTIONS AND FOR THE TREATMENT OF AFFECTIONS THAT IMPROVE THROUGH AN INCREASE IN THE BLOOD CONCENTRATION OF GLP-1
PE20071221A1 (en) 2006-04-11 2007-12-14 Arena Pharm Inc GPR119 RECEPTOR AGONISTS IN METHODS TO INCREASE BONE MASS AND TO TREAT OSTEOPOROSIS AND OTHER CONDITIONS CHARACTERIZED BY LOW BONE MASS, AND COMBINED THERAPY RELATED TO THESE AGONISTS
EP1971862B1 (en) 2006-04-11 2010-11-10 Arena Pharmaceuticals, Inc. Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
CN101801954B (en) 2007-09-20 2013-10-09 Irm责任有限公司 Compounds and compositions as modulators of GPR119 activity
EP2146210A1 (en) * 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
NZ596445A (en) 2009-06-24 2013-04-26 Boehringer Ingelheim Int New compounds, pharmaceutical composition and methods relating thereto
JP2012530758A (en) 2009-06-24 2012-12-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Novel compounds, pharmaceutical compositions and methods relating thereto
AR077642A1 (en) 2009-07-09 2011-09-14 Arena Pharm Inc METABOLISM MODULATORS AND THE TREATMENT OF DISORDERS RELATED TO THE SAME
WO2011113947A1 (en) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
EP2556056A1 (en) 2010-04-06 2013-02-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012025811A1 (en) 2010-08-23 2012-03-01 Lupin Limited Indolylpyrimidines as modulators of gpr119
SG188548A1 (en) 2010-09-22 2013-04-30 Arena Pharm Inc Modulators of the gpr119 receptor and the treatment of disorders related thereto
AU2011333472A1 (en) 2010-11-26 2013-06-06 Lupin Limited Bicyclic GPR119 modulators
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140066369A1 (en) 2011-04-19 2014-03-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012170867A1 (en) 2011-06-09 2012-12-13 Rhizen Pharmaceuticals Sa Novel compounds as modulators of gpr-119
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
JP2015522080A (en) 2012-07-11 2015-08-03 エルセリクス セラピューティクス インコーポレイテッド Compositions for reducing cardiovascular metabolic risk comprising statins, biguanides, and additional agents
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
NZ734220A (en) 2015-01-06 2022-01-28 Arena Pharm Inc Methods of treating conditions related to the s1p1 receptor
KR200481746Y1 (en) 2015-01-21 2016-11-04 큰길엔터프라이즈 주식회사 Natural humidifier
CN108349891B (en) 2015-06-22 2022-04-05 艾尼纳制药公司 Crystalline L-arginine salt of a compound for use in S1P1 receptor-related disorders
WO2018151873A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
WO2018236896A1 (en) 2017-06-19 2018-12-27 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of nafld and nash
JP2023526625A (en) 2020-05-19 2023-06-22 キャリーオペ，インク． AMPK Activator
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators

Family Cites Families (191)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4704362A (en) * 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4495002A (en) * 1981-05-27 1985-01-22 Westinghouse Electric Corp. Three-step treatment of stainless steels having metastable austenitic and martensitic phases to increase resistance to chloride corrosion
US5462856A (en) * 1990-07-19 1995-10-31 Bunsen Rush Laboratories, Inc. Methods for identifying chemicals that act as agonists or antagonists for receptors and other proteins involved in signal transduction via pathways that utilize G-proteins
CA2121369C (en) 1991-10-22 2003-04-29 William W. Bachovchin Inhibitors of dipeptidyl-aminopeptidase type iv
MX9206628A (en) 1991-11-22 1993-05-01 Boehringer Ingelheim Pharma PROLINABORONATE ESTER AND METHOD FOR ITS PREPARATION.
US6100042A (en) 1993-03-31 2000-08-08 Cadus Pharmaceutical Corporation Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
DE19616486C5 (en) 1996-04-25 2016-06-30 Royalty Pharma Collection Trust Method for lowering the blood glucose level in mammals
US20020006899A1 (en) 1998-10-06 2002-01-17 Pospisilik Andrew J. Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
US6040145A (en) 1997-05-07 2000-03-21 Tufts University Potentiation of the immune response
US6100234A (en) 1997-05-07 2000-08-08 Tufts University Treatment of HIV
US6183974B1 (en) 1997-07-31 2001-02-06 The General Hospital Corporation Screening assays for G protein coupled receptor agonists and antagonists
GB9719496D0 (en) 1997-09-13 1997-11-19 Glaxo Group Ltd G protien chimeras
WO1999025719A1 (en) 1997-11-18 1999-05-27 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Novel physiologically active substance sulphostin, process for producing the same, and use thereof
WO1999038501A2 (en) 1998-02-02 1999-08-05 Trustees Of Tufts College Method of regulating glucose metabolism, and reagents related thereto
US5922576A (en) * 1998-02-27 1999-07-13 The John Hopkins University Simplified system for generating recombinant adenoviruses
US6304621B1 (en) 1998-05-13 2001-10-16 Broadcom Corporation Multi-mode variable rate digital cable receiver
DE19823831A1 (en) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim New pharmaceutical use of isoleucyl thiazolidide and its salts
DE19828113A1 (en) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs of Dipeptidyl Peptidase IV Inhibitors
DE19828114A1 (en) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs of unstable inhibitors of dipeptidyl peptidase IV
DE19834591A1 (en) 1998-07-31 2000-02-03 Probiodrug Ges Fuer Arzneim Use of substances that decrease the activity of dipeptidyl peptidase IV to increase blood sugar levels, e.g. for treating hypoglycemia
AU5190499A (en) 1998-08-06 2000-02-28 Shmuel Peltz Method and appliances for electrostimulation
KR20010079669A (en) 1998-08-21 2001-08-22 바바라 피. 월너 Regulation of Substrate Activity
JP2002523090A (en) 1998-09-01 2002-07-30 ビーエーエスエフ アクチェンゲゼルシャフト Enhanced functional expression of heterologous G protein-coupled receptors
WO2000020592A1 (en) 1998-10-07 2000-04-13 Medical College Of Georgia Research Institute, Inc. Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
US6242422B1 (en) 1998-10-22 2001-06-05 Idun Pharmacueticals, Inc. (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
KR100926209B1 (en) 1998-11-20 2009-11-09 아레나 파마슈티칼스, 인크. Human Orphan G Protein-Coupled Receptors
CO5150173A1 (en) 1998-12-10 2002-04-29 Novartis Ag COMPOUNDS N- (REPLACED GLYCLE) -2-DIPEPTIDYL-IV PEPTIDASE INHIBITING CYANOPIRROLIDINS (DPP-IV) WHICH ARE EFFECTIVE IN THE TREATMENT OF CONDITIONS MEDIATED BY DPP-IV INHIBITION
JP2000191616A (en) 1998-12-24 2000-07-11 Senju Pharmaceut Co Ltd New peptidylaldehyde derivative and medicine containing the same
US20030125539A1 (en) * 1999-02-22 2003-07-03 Synaptic Pharmaceutical Corporation DNA encoding SNORF25 receptor
US6221660B1 (en) * 1999-02-22 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding SNORF25 receptor
JP4121215B2 (en) 1999-05-17 2008-07-23 財団法人微生物化学研究会 Sulfostin analog, and method for producing sulfostine and its analog
JP4028135B2 (en) 1999-05-27 2007-12-26 本田技研工業株式会社 Object detection device
US6617340B1 (en) 1999-07-29 2003-09-09 Novartis Ag N-(substituted glycyl)-pyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
DE19940130A1 (en) 1999-08-24 2001-03-01 Probiodrug Ges Fuer Arzneim New effectors of Dipeptidyl Peptidase IV for topical use
US6653064B1 (en) 1999-09-23 2003-11-25 Boehringer Ingelheim International Gmbh Method for identifying compounds useful in the therapy of bone disorders
GB9923177D0 (en) 1999-09-30 1999-12-01 Pfizer Ltd Novel polypeptide
JP2003535034A (en) 1999-11-12 2003-11-25 ギルフォード ファーマシューティカルズ インコーポレイテッド Dipeptidyl peptidase IV inhibitors and methods for producing and using dipeptidyl peptidase IV inhibitors
US6380398B2 (en) 2000-01-04 2002-04-30 Novo Nordisk A/S Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV
DE60132723T2 (en) 2000-01-21 2009-01-29 Novartis Pharma Ag Compositions consisting of dipeptidyl peptidase IV inhibitors and antidiabetics
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US6608038B2 (en) 2000-03-15 2003-08-19 Novartis Ag Methods and compositions for treatment of diabetes and related conditions via gene therapy
EP2336169A1 (en) 2000-04-21 2011-06-22 New England Medical Center Hospital G protein coupled receptor (GPCR) agonists and antagonists and methods of activating and inhibiting GPCR using the same
GB0010183D0 (en) 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
GB0010188D0 (en) 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
ATE348162T1 (en) 2000-05-18 2007-01-15 Bayer Healthcare Ag REGULATION OF A HUMAN DOPAMINE-LIKE G-PROTEIN COUPLED RECEPTOR.
US6432969B1 (en) 2000-06-13 2002-08-13 Novartis Ag N-(substituted glycyl)-2 cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
TW583185B (en) 2000-06-13 2004-04-11 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same
AU6895801A (en) 2000-07-04 2002-01-14 Novo Nordisk As Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv
AU7705601A (en) 2000-07-25 2002-02-05 Merck & Co Inc N-substituted indoles useful in the treatment of diabetes
WO2002014271A1 (en) 2000-08-10 2002-02-21 Mitsubishi Pharma Corporation Proline derivatives and use thereof as drugs
US20040005555A1 (en) 2000-08-31 2004-01-08 Rothman Richard E. Molecular diagnosis of bactermia
TWI290919B (en) 2000-10-06 2007-12-11 Tanabe Seiyaku Co Nitrogen-containing five-membered ring compound, a pharmacologically permissible salt thereof and the method for producing the same
JP2004035574A (en) 2000-10-06 2004-02-05 Tanabe Seiyaku Co Ltd Aliphatic nitrogenous five-membered ring compound
JP4329290B2 (en) 2000-10-06 2009-09-09 田辺三菱製薬株式会社 Aliphatic nitrogen-containing five-membered ring compounds
JP4329291B2 (en) 2000-10-06 2009-09-09 田辺三菱製薬株式会社 Nitrogen-containing five-membered ring compounds
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
AU1989002A (en) 2000-11-27 2002-06-03 Arena Pharm Inc Endogenous and non-endogenous versions of human g protein-coupled receptors
ES2280435T3 (en) 2000-12-01 2007-09-16 Astellas Pharma Inc. METHOD OF EXPLORATION OF REMEDIES FOR DIABETES.
US20040180925A1 (en) 2000-12-27 2004-09-16 Kenji Matsuno Dipeptidylpeptidase-IV inhibitor
JP4823431B2 (en) 2001-01-30 2011-11-24 東レ・ダウコーニング株式会社 Room temperature curable silicone rubber composition
JP4213390B2 (en) 2001-02-02 2009-01-21 武田薬品工業株式会社 Fused heterocyclic compounds
DK1953162T3 (en) 2001-02-24 2012-09-10 Boehringer Ingelheim Pharma Xanthine derivatives, their preparation and their use as a drug.
JP2002265439A (en) 2001-03-08 2002-09-18 Mitsubishi Pharma Corp Cyanopyrrolidine derivative and its use for medicine
ATE395912T1 (en) 2001-03-27 2008-06-15 Merck & Co Inc DIPEPTIDYLPEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
WO2002080860A2 (en) 2001-03-27 2002-10-17 The Regents Of The University Of California Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism
FR2822826B1 (en) 2001-03-28 2003-05-09 Servier Lab NOVEL ALPHA-AMINO ACID SULPHONYL DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
US6573287B2 (en) 2001-04-12 2003-06-03 Bristo-Myers Squibb Company 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
US20020192206A1 (en) 2001-05-05 2002-12-19 Kozarov Emil V. Methods and compositions for angioproliferative disorder treatment
FR2824825B1 (en) 2001-05-15 2005-05-06 Servier Lab NOVEL ALPHA-AMINOACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
JP2003000977A (en) 2001-06-26 2003-01-07 Juki Corp Bag-cloth feeder of binding sewing machine
US20030130199A1 (en) 2001-06-27 2003-07-10 Von Hoersten Stephan Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
US7368421B2 (en) 2001-06-27 2008-05-06 Probiodrug Ag Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
US6869947B2 (en) 2001-07-03 2005-03-22 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US6740250B2 (en) 2001-07-13 2004-05-25 Hazard Control Technologies Fire suppressant having foam stabilizer
DE10143840A1 (en) 2001-09-06 2003-03-27 Probiodrug Ag New acylated hydroxamates useful for the treatment of e.g. wound healing
US6844316B2 (en) 2001-09-06 2005-01-18 Probiodrug Ag Inhibitors of dipeptidyl peptidase I
CN100341862C (en) 2001-09-14 2007-10-10 三菱制药株式会社 Thiazolidine derivative and medicinal use thereof
JPWO2003026661A1 (en) 2001-09-14 2005-01-06 山之内製薬株式会社 Insulin secretion promoter and novel pyrimidine derivatives
JP2005509603A (en) 2001-09-19 2005-04-14 ノボ　ノルディスク　アクティーゼルスカブ Heterocyclic compounds that are inhibitors of the DPP-IV enzyme
US7238671B2 (en) 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
JP2005514337A (en) 2001-10-18 2005-05-19 ブリストル−マイヤーズ　スクイブ　カンパニー Human glucagon-like peptide-1 mimics and their use in the treatment of diabetes and related diseases
GB0125446D0 (en) 2001-10-23 2001-12-12 Ferring Bv Novel anti-diabetic agents
US6861440B2 (en) 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
US20030125304A1 (en) 2001-11-09 2003-07-03 Hans-Ulrich Demuth Substituted amino ketone compounds
WO2003045977A2 (en) 2001-11-26 2003-06-05 Trustees Of Tufts College Peptidomimetic Inhibitors of Post-Proline Cleaving Enzymes
CA2466870A1 (en) 2001-11-26 2003-06-05 Trustees Of Tufts College Methods for treating autoimmune disorders, and reagents related thereto
WO2003057144A2 (en) 2001-12-26 2003-07-17 Guilford Pharmaceuticals Change inhibitors of dipeptidyl peptidase iv
US6727261B2 (en) 2001-12-27 2004-04-27 Hoffman-La Roche Inc. Pyrido[2,1-A]Isoquinoline derivatives
WO2003072528A2 (en) 2002-02-08 2003-09-04 Idun Pharmaceuticals, Inc. (substituted)acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
ES2345096T3 (en) 2002-02-13 2010-09-15 F. Hoffmann-La Roche Ag NEW DERIVATIVES OF PIRIDINA AND PIRIMIDINA.
CN1308311C (en) 2002-02-13 2007-04-04 霍夫曼-拉罗奇有限公司 Novel pyridine- and quinoline-derivatives
US6906074B2 (en) 2002-02-22 2005-06-14 Nippon Zoki Pharmaceutical Co., Ltd. 2-phenylpiperazine derivatives
JP2004043429A (en) 2002-02-25 2004-02-12 Eisai Co Ltd New xanthine derivative and dppiv inhibitor
DE60304911D1 (en) 2002-02-25 2006-06-08 Eisai Co Ltd Xanthine derivatives as DPP-IV inhibitors
EA007434B1 (en) 2002-02-28 2006-10-27 Прозидион Лимитед Glutaminyl based dpiv inhibitors
HUP0200849A2 (en) * 2002-03-06 2004-08-30 Sanofi-Synthelabo N-aminoacetyl-pyrrolidine-2-carbonitrile derivatives, pharmaceutical compositions containing them and process for producing them
EP1490335B1 (en) 2002-03-25 2007-09-19 Merck & Co., Inc. Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2003080633A1 (en) 2002-03-25 2003-10-02 Nippon Kayaku Kabushiki Kaisha Novel $g(a)-amino-n-(diaminophosphinyl)lactam derivative
JP4329381B2 (en) 2002-04-04 2009-09-09 田辺三菱製薬株式会社 Pharmaceutical composition
JP4329382B2 (en) 2002-04-04 2009-09-09 田辺三菱製薬株式会社 Pharmaceutical composition
JP2005532283A (en) 2002-04-08 2005-10-27 トレント・ファーマシューティカルズ・リミテッド Thiazolidine-4-carbonitrile and the like and their use as dipeptidyl-peptidase inhibitors
JP2003300977A (en) 2002-04-10 2003-10-21 Sumitomo Pharmaceut Co Ltd Xanthine derivative
JP2004026820A (en) 2002-05-09 2004-01-29 Taisho Pharmaceut Co Ltd Dipeptidyl peptidase iv inhibitor
JP2003327532A (en) 2002-05-10 2003-11-19 Takeda Chem Ind Ltd Peptidase inhibitor
US6710040B1 (en) 2002-06-04 2004-03-23 Pfizer Inc. Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
WO2003101449A2 (en) 2002-06-04 2003-12-11 Pfizer Products Inc. Process for the preparation of 3,3,4,4-tetrafluoropyrrolidine and derivatives thereof
NZ536794A (en) 2002-06-06 2007-04-27 Eisai Co Ltd Condensed imidazole derivatives
JP2004026678A (en) 2002-06-24 2004-01-29 Microbial Chem Res Found Therapeutic agent for type 2 diabetes
US6833973B2 (en) 2002-06-27 2004-12-21 International Business Machines Corporation Apparatus and method to calibrate a servo sensor
DE60330485D1 (en) 2002-07-15 2010-01-21 Merck & Co Inc FOR THE TREATMENT OF DIABETES
JP4542757B2 (en) 2002-08-08 2010-09-15 武田薬品工業株式会社 Fused heterocyclic compounds
WO2004034968A2 (en) * 2002-08-20 2004-04-29 The Regents Of The University Of California Combination therapy for controlling appetites
DE10238243A1 (en) 2002-08-21 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg New 8-(3-amino-piperidin-1-yl)-xanthine derivatives are dipeptidylpeptidase-IV inhibitors useful for, e.g. treating diabetes mellitus, arthritis or obesity
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE10238477A1 (en) 2002-08-22 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg New purine derivatives, their production and their use as medicines
DE10238470A1 (en) 2002-08-22 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg New xanthine derivatives, their production and their use as medicines
US20060039974A1 (en) 2002-09-11 2006-02-23 Takeda Pharmaceutical Company Limited Sustained release preparation
WO2004024943A1 (en) 2002-09-11 2004-03-25 Yamanouchi Pharmaceutical Co., Ltd. Method of screening insulin content enhancer
US7482337B2 (en) 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10251927A1 (en) 2002-11-08 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg New 1,7,8-trisubstituted xanthine derivatives, are dipeptidylpeptidase-IV inhibitors useful e.g. for treating diabetes mellitus type I or II, arthritis or obesity
JP2006508975A (en) 2002-11-18 2006-03-16 ファイザー・プロダクツ・インク Fluorinated cyclic amides that inhibit dipeptidyl peptidase IV
DE10256264A1 (en) 2002-12-03 2004-06-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg New trisubstituted dihydro-imidazo-pyridazinone or imidazo-pyridinone derivatives, useful as dipeptidylpeptidase-IV inhibitors for e.g. treating diabetes mellitus type I or II, arthritis or obesity
CA2508487A1 (en) 2002-12-04 2004-06-17 Merck & Co., Inc. Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
JP4504924B2 (en) 2002-12-20 2010-07-14 メルク・シャープ・エンド・ドーム・コーポレイション 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment and prevention of diabetes
RS20050532A (en) 2003-01-14 2007-12-31 Arena Pharmaceuticals Inc., 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
US7265128B2 (en) 2003-01-17 2007-09-04 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
JP2004244412A (en) 2003-01-20 2004-09-02 Kotobuki Seiyaku Kk 2-cyanopyrrolidine derivative having substituent at 4-position, method for producing the same, and medicament containing the same
CA2513684A1 (en) 2003-01-31 2004-08-19 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
PL378295A1 (en) 2003-02-24 2006-03-20 Arena Pharmaceuticals, Inc. Substituted aryl and heteroaryl derivatives as modulators of glucose metabolism and the prophylaxis and treatment of disorders thereof
JP2004269469A (en) 2003-03-12 2004-09-30 Yamanouchi Pharmaceut Co Ltd Pyrimidine derivative or salt thereof
JP2004269468A (en) 2003-03-12 2004-09-30 Yamanouchi Pharmaceut Co Ltd Pyrimidine derivative or salt thereof
ATE462432T1 (en) 2003-05-05 2010-04-15 Probiodrug Ag GLUTAMINYL CYCLASE INHIBITORS
US7083933B1 (en) 2003-05-09 2006-08-01 Prosidion Limited Methods for identification of modulators of OSGPR116 activity
CA2524531A1 (en) 2003-05-14 2004-12-02 Merck And Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2004103993A1 (en) 2003-05-14 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
US20060293297A1 (en) 2003-05-15 2006-12-28 Hiroshi Fukushima Cyanofluoropyrrolidine derviative
DE10327439A1 (en) 2003-06-18 2005-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel imidazopyridazinone and imidazopyridone derivatives, their production and their use as pharmaceuticals
BRPI0411713B8 (en) 2003-06-20 2021-05-25 Hoffmann La Roche compounds, process for their manufacture, pharmaceutical compositions comprising them, method for treatment and/or prophylaxis of diseases that are associated with dpp-iv and their use
AU2004251829B2 (en) 2003-06-20 2009-12-17 F. Hoffmann-La Roche Ag Hexahydropyridoisoqinolines as DPP-IV inhibitors
JP2005019000A (en) 2003-06-23 2005-01-20 Inter Media:Kk Illumination control system
JO2625B1 (en) 2003-06-24 2011-11-01 ميرك شارب اند دوم كوربوريشن Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
JP2005018412A (en) 2003-06-26 2005-01-20 Toppan Printing Co Ltd Electronic purchasing system and method
JP2005023038A (en) 2003-07-04 2005-01-27 Taisho Pharmaceut Co Ltd Therapeutic agent for chronic renal disease
AR045047A1 (en) 2003-07-11 2005-10-12 Arena Pharm Inc ARILO AND HETEROARILO DERIVATIVES TRISUSTITUIDOS AS MODULATORS OF METABOLISM AND PROFILAXIS AND TREATMENT OF DISORDERS RELATED TO THEMSELVES
MXPA06000554A (en) 2003-07-14 2006-07-03 Arena Pharm Inc Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto.
DE10333935A1 (en) 2003-07-25 2005-02-24 Aventis Pharma Deutschland Gmbh New bicyclic cyano-heterocycles, process for their preparation and their use as pharmaceuticals
US7094800B2 (en) 2003-07-25 2006-08-22 Sanofi-Aventis Deutschland Gmbh Cyanopyrrolidides, process for their preparation and their use as medicaments
US7008957B2 (en) 2003-07-25 2006-03-07 Sanofi-Aventis Deutschland Gmbh Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments
US6995183B2 (en) 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
WO2005019168A2 (en) 2003-08-20 2005-03-03 Pfizer Products Inc. Fluorinated lysine derivatives as dipeptidyl peptidase iv inhibitors
EP1659123A1 (en) 2003-08-29 2006-05-24 Dainippon Sumitomo Pharma Co., Ltd. Bicyclic pyrazole derivative
HU227684B1 (en) 2003-08-29 2011-11-28 Sanofi Aventis Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors
EP1671649B1 (en) 2003-10-03 2011-11-23 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase IV inhibitors for treating diabetic patients with sulfonylurea secondary failure
DE10355304A1 (en) * 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel 8- (piperazin-1-yl) and 8 - ([1,4] diazepan-1-yl) xanthines, their preparation and their use as pharmaceuticals
US7217711B2 (en) * 2003-12-17 2007-05-15 Boehringer Ingelheim International Gmbh Piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutical compositions
NZ547965A (en) 2003-12-24 2009-12-24 Prosidion Ltd 1,2,4-Oxadiazole derivatives as GPCR receptor agonists
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004009039A1 (en) * 2004-02-23 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8- [3-Amino-piperidin-1-yl] xanthines, their preparation and use as pharmaceuticals
ATE415397T1 (en) 2004-06-04 2008-12-15 Arena Pharm Inc SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND FOR THE PROPHYLAXIS AND TREATMENT OF RELATED DISEASES
WO2006000577A2 (en) 2004-06-24 2006-01-05 Galapagos N.V. Lxr agonists to promote bone homeostasis
US20060024313A1 (en) 2004-07-06 2006-02-02 Xin Chen Agents that disrupt dimer formation in DPP-IV family of prolyl dipeptidases
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US20060046978A1 (en) 2004-08-31 2006-03-02 Morphochem Ag Novel compounds that inhibit dipeptidyl peptidase (DPP-IV) and neprilysin (NEP) and/or angiotensin converting enzyme (ACE)
DE102004044221A1 (en) 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg New 3-methyl-7-butynyl xanthines, their preparation and their use as pharmaceuticals
CN101048368A (en) * 2004-10-07 2007-10-03 默克公司 Acyclic hydrazides as cannabinoid receptor modulators
CA2583259C (en) 2004-10-08 2011-08-02 Astellas Pharma Inc. Aromatic ring fused pyrimidine derivative
TW200621257A (en) 2004-10-20 2006-07-01 Astellas Pharma Inc Pyrimidine derivative fused with nonaromatic ring
US7411093B2 (en) 2004-12-20 2008-08-12 Hoffman-La Roche Inc. Aminocycloalkanes as DPP-IV inhibitors
EP1828192B1 (en) 2004-12-21 2014-12-03 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CA2591922A1 (en) 2004-12-24 2006-06-29 Prosidion Limited G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes
US8193359B2 (en) 2004-12-24 2012-06-05 Prosidion Limited G-protein coupled receptor agonists
US7589088B2 (en) 2004-12-29 2009-09-15 Bristol-Myers Squibb Company Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
GB0428514D0 (en) 2004-12-31 2005-02-09 Prosidion Ltd Compounds
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
DOP2006000008A (en) 2005-01-10 2006-08-31 Arena Pharm Inc COMBINED THERAPY FOR THE TREATMENT OF DIABETES AND RELATED AFFECTIONS AND FOR THE TREATMENT OF AFFECTIONS THAT IMPROVE THROUGH AN INCREASE IN THE BLOOD CONCENTRATION OF GLP-1
US20070032420A1 (en) 2005-02-09 2007-02-08 Entelos, Inc. Treating diabetes with glucagon-like peptide-1 secretagogues
EP1902730A4 (en) 2005-06-09 2009-11-11 Banyu Pharma Co Ltd Npy y2 agonist for use as therapeutic agent for disease accompanied by diarrhea
JP5114395B2 (en) 2005-06-30 2013-01-09 プロシディオン・リミテッド GPCR agonist
AU2006264651A1 (en) 2005-06-30 2007-01-11 Prosidion Limited G-protein coupled receptor agonists
BRPI0613505A2 (en) 2005-06-30 2011-01-11 Prosidion Ltd gpcr agonists
EP1907384A2 (en) 2005-06-30 2008-04-09 Prosidion Limited Gpcr agonists
US7708191B2 (en) * 2005-07-28 2010-05-04 Edwin Vega Telebanking apparatus for transferring money or cash value between two parties in the same country or across national borders, for paying bills and browsing the internet
PE20071221A1 (en) 2006-04-11 2007-12-14 Arena Pharm Inc GPR119 RECEPTOR AGONISTS IN METHODS TO INCREASE BONE MASS AND TO TREAT OSTEOPOROSIS AND OTHER CONDITIONS CHARACTERIZED BY LOW BONE MASS, AND COMBINED THERAPY RELATED TO THESE AGONISTS
EP1971862B1 (en) 2006-04-11 2010-11-10 Arena Pharmaceuticals, Inc. Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
US20080103123A1 (en) 2006-08-30 2008-05-01 Biovitrum New compounds
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY

Also Published As

Publication number Publication date
JP4762359B2 (en) 2011-08-31
EP1971862A2 (en) 2008-09-24
EP2369341A2 (en) 2011-09-28
US8017574B2 (en) 2011-09-13
AR060406A1 (en) 2008-06-11
JP2009254375A (en) 2009-11-05
ZA200807997B (en) 2011-05-25
ECSP088817A (en) 2008-11-27
BRPI0710597A2 (en) 2012-06-19
KR101281962B1 (en) 2013-07-08
US8026212B2 (en) 2011-09-27
US20100203038A1 (en) 2010-08-12
US20120059166A1 (en) 2012-03-08
US8580526B2 (en) 2013-11-12
CN103323606A (en) 2013-09-25
EP2369341A3 (en) 2012-01-04
CN101421618B (en) 2013-11-20
RS51745B (en) 2011-10-31
NO20084746L (en) 2009-01-09
AU2007238805A1 (en) 2007-10-25
EP2410330A2 (en) 2012-01-25
SG10201404220TA (en) 2014-10-30
EA201101475A1 (en) 2012-07-30
DK1971862T3 (en) 2011-02-14
JP2011101640A (en) 2011-05-26
PL1971862T3 (en) 2011-04-29
MA30555B1 (en) 2009-07-01
JP2009240328A (en) 2009-10-22
EP1971862B1 (en) 2010-11-10
HK1117911A1 (en) 2009-01-23
GT200800207A (en) 2010-03-09
NZ571110A (en) 2011-03-31
ES2354390T3 (en) 2011-03-14
JP2011103887A (en) 2011-06-02
PT1971862E (en) 2011-02-14
CL2007001011A1 (en) 2008-05-16
US7833730B2 (en) 2010-11-16
TWI409458B (en) 2013-09-21
TNSN08396A1 (en) 2010-04-14
TW200809200A (en) 2008-02-16
CA2618488C (en) 2010-07-13
EP2402750A1 (en) 2012-01-04
US8026074B2 (en) 2011-09-27
WO2007120689A2 (en) 2007-10-25
CR10337A (en) 2009-01-19
JP5415856B2 (en) 2014-02-12
JP4521838B2 (en) 2010-08-11
EP2410330A3 (en) 2012-06-13
ATE487940T1 (en) 2010-11-15
CY1111123T1 (en) 2015-06-11
WO2007120689A3 (en) 2008-05-29
US20100068700A1 (en) 2010-03-18
US20100203577A1 (en) 2010-08-12
MEP27308A (en) 2010-06-10
AU2007238805B2 (en) 2012-04-05
EA200870424A1 (en) 2009-06-30
HRP20110068T1 (en) 2011-02-28
CN101421618A (en) 2009-04-29
CN103536924A (en) 2014-01-29
JP2011072312A (en) 2011-04-14
EA016041B1 (en) 2012-01-30
US20100203037A1 (en) 2010-08-12
UA97479C2 (en) 2012-02-27
DE602007010420D1 (en) 2010-12-23
KR20090007409A (en) 2009-01-16
MX2008013120A (en) 2008-10-27
SI1971862T1 (en) 2011-02-28
JP2009533055A (en) 2009-09-17

Similar Documents

Publication Publication Date Title
CA2618488A1 (en) Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
CA2654733A1 (en) Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level
JP2009254375A5 (en)
Ray et al. Expression of the calcium-sensing receptor on human antral gastrin cells in culture.
AR071127A1 (en) METHODS OF USE OF A PROTEIN G COUPLED RECEIVER TO IDENTIFY PEPTIDE SECRETAGOGOS YY (PYY) AND USEFUL COMPOUNDS IN THE TREATMENT OF AFFECTION MODULATED BY PYY
Gharahdaghi et al. Peptide-mass profiles of polyvinylidene difluoride-bound proteins by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry in the presence of nonionic detergents
Rene et al. Subtype analysis of Blastocystis isolates from Blastocystis cyst excreting patients
EP1860186A3 (en) Method for distinguishing mesenchymal stem cells using different markers
WO2008087035A3 (en) Screening method for anti-diabetic compounds
CA2581226A1 (en) Thermostable mutants of pyrroloquinoline quinone dependent glucose dehydrogenase
JP2005537027A5 (en)
US7198914B2 (en) Guanosine triphosphate (GTP)-binding protein-coupled receptor protein, BG37
Predel et al. Tachykinin‐related peptide precursors in two cockroach species: Molecular cloning and peptide expression in brain neurons and intestine
KR100878959B1 (en) Screening method
RU2011143788A (en) METHOD FOR DETECTING ANTI-SITH-1 ANTIBODIES IN A BIOLOGICAL SAMPLE
Roth et al. Quantitative proteomics identifies a change in glial glutamate metabolism at the time of female puberty
Guo et al. Regulation of cardiac Kv1. 5 K+ channel expression by cardiac fibroblasts and mechanical load in cultured newborn rat ventricular myocytes
WO2010051204A4 (en) Bcr-abl variants
EP2517002A4 (en) Insulin receptor substrate 1 (irs1) protein srm/mrm assay
Veelaert et al. Identification of a new tachykinin from the midgut of the desert locust, Schistocerca gregaria, by ESI-Qq-oa-TOF mass spectrometry
EP2046997A2 (en) A common gene expression signature in dilated cardiomyopathy
Fujii et al. Effects of endothelin‐1 on Ca2+ signaling and secretion in parathyroid cells
Wendel-Wellner et al. Cellular localization of the endothelin receptor subtypes ET A and ET B in the rat heart and their differential expression in coronary arteries, veins, and capillaries
Kodama et al. Dimerization of neurokin A and B COOH-terminal heptapeptide fragments enhanced the selectivity for tachykinin receptor subtypes
CA2374377A1 (en) Potassium channel kcnq5

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160411